Trial Profile
A phase IIb proof-of-concept study of RPL-554 in patients with cystic-fibrosis
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 10 Aug 2017
Price :
$35
*
At a glance
- Drugs Ensifentrine (Primary)
- Indications Cystic fibrosis
- Focus Proof of concept; Therapeutic Use
- 10 Aug 2017 New trial record
- 08 Aug 2017 According to a Verona Pharma media release, the company is planning to initiate this study in the year 2018.